232 related articles for article (PubMed ID: 1724760)
21. Calcium channel agonist and antagonist binding in a highly enriched sarcolemma preparation obtained from canine ventricle.
Rampe D; Poder T; Zhao ZY; Schilling WP
J Cardiovasc Pharmacol; 1989 Apr; 13(4):547-56. PubMed ID: 2470991
[TBL] [Abstract][Full Text] [Related]
22. Separate [3H]-nitrendipine binding sites in mitochondria and plasma membranes of bovine adrenal medulla.
Ballesta JJ; Garcia AG; Gutierrez LM; Hidalgo MJ; Palmero M; Reig JA; Viniegra S
Br J Pharmacol; 1990 Sep; 101(1):21-6. PubMed ID: 1704272
[TBL] [Abstract][Full Text] [Related]
23. Solubilization of calcium channel antagonist binding sites from rat brain.
Finkel MS; Tallman JF
J Neurochem; 1987 Sep; 49(3):921-7. PubMed ID: 2440991
[TBL] [Abstract][Full Text] [Related]
24. [3H]HOE166 defines a novel calcium antagonist drug receptor--distinct from the 1,4 dihydropyridine binding domain.
Grassegger A; Striessnig J; Weiler M; Knaus HG; Glossmann H
Naunyn Schmiedebergs Arch Pharmacol; 1989 Dec; 340(6 Pt 2):752-9. PubMed ID: 2561307
[TBL] [Abstract][Full Text] [Related]
25. Binding of Ca2+ entry blockers to cardiac sarcolemmal membrane vesicles. Characterization of diltiazem-binding sites and their interaction with dihydropyridine and aralkylamine receptors.
Garcia ML; King VF; Siegl PK; Reuben JP; Kaczorowski GJ
J Biol Chem; 1986 Jun; 261(18):8146-57. PubMed ID: 2424894
[TBL] [Abstract][Full Text] [Related]
26. Dihydropyridine binding sites in aerobically perfused, ischemic, and reperfused rat hearts: effect of temperature and time.
Gu XH; Dillon JS; Nayler WG
J Cardiovasc Pharmacol; 1988 Sep; 12(3):272-8. PubMed ID: 2464098
[TBL] [Abstract][Full Text] [Related]
27. Purification of a functional receptor for calcium-channel blockers from rabbit skeletal-muscle microsomes.
Flockerzi V; Oeken HJ; Hofmann F
Eur J Biochem; 1986 Nov; 161(1):217-24. PubMed ID: 3023084
[TBL] [Abstract][Full Text] [Related]
28. A comparison between the binding and electrophysiological effects of dihydropyridines on cardiac membranes.
Hamilton SL; Yatani A; Brush K; Schwartz A; Brown AM
Mol Pharmacol; 1987 Mar; 31(3):221-31. PubMed ID: 2436031
[TBL] [Abstract][Full Text] [Related]
29. Purification of the dihydropyridine receptor of the voltage-dependent Ca2+ channel from skeletal muscle transverse tubules using (+) [3H]PN 200-110.
Borsotto M; Barhanin J; Norman RI; Lazdunski M
Biochem Biophys Res Commun; 1984 Aug; 122(3):1357-66. PubMed ID: 6089781
[TBL] [Abstract][Full Text] [Related]
30. Effects of diltiazem and verapamil on (+)-PN 200-110 binding kinetics in dog cardiac membranes.
Miwa K; Miyagi Y; Araie E; Sasayama S
Eur J Pharmacol; 1992 Apr; 214(2-3):127-32. PubMed ID: 1325351
[TBL] [Abstract][Full Text] [Related]
31. [3H]diltiazem binding to calcium channel antagonists recognition sites in rat cerebral cortex.
Schoemaker H; Langer SZ
Eur J Pharmacol; 1985 May; 111(2):273-7. PubMed ID: 2410283
[TBL] [Abstract][Full Text] [Related]
32. Calcium antagonist binding sites in failing and nonfailing human ventricular myocardium.
Rasmussen RP; Minobe W; Bristow MR
Biochem Pharmacol; 1990 Feb; 39(4):691-6. PubMed ID: 2154992
[TBL] [Abstract][Full Text] [Related]
33. Interaction of the calcium channel activating 3H-BAY K 8644 and inhibiting 3H-verapamil with specific receptor sites on cultured beating myocardial cells.
Bellemann P
J Recept Res; 1984; 4(1-6):571-85. PubMed ID: 6084713
[TBL] [Abstract][Full Text] [Related]
34. Dihydropyridine-sensitive Ca2+ channels: molecular properties of interaction with Ca2+ channel blockers, purification, subunit structure, and differentiation.
Lazdunski M; Barhanin J; Borsotto M; Fosset M; Galizzi JP; Renaud JF; Romey G; Schmid A
J Cardiovasc Pharmacol; 1986; 8 Suppl 8():S13-9. PubMed ID: 2433514
[TBL] [Abstract][Full Text] [Related]
35. Regulation of 1,4-dihydropyridine and beta-adrenergic receptor sites in coronary artery smooth muscle membranes.
Drimal J
Cell Signal; 1991; 3(3):225-32. PubMed ID: 1716451
[TBL] [Abstract][Full Text] [Related]
36. Competitive binding experiments reveal differential interactions for dihydropyridine calcium channel activators and antagonists at dihydropyridine receptors on mouse brain membranes.
O'Neill SK; Triggle CR; Bolger GT
Can J Physiol Pharmacol; 1994 Jul; 72(7):738-45. PubMed ID: 7530159
[TBL] [Abstract][Full Text] [Related]
37. Protection by verapamil and nifedipine against ischaemia-induced loss of [3H]-(+)-PN 200-110 binding sites in the rat heart.
van Amsterdam FT; van Amsterdam-Magnoni MS; Haas M; Punt NC; Zaagsma J
Naunyn Schmiedebergs Arch Pharmacol; 1990; 341(1-2):137-42. PubMed ID: 2156175
[TBL] [Abstract][Full Text] [Related]
38. Correlation between the negative inotropic potency and binding parameters of 1,4-dihydropyridine and phenylalkylamine calcium channel blockers in cat heart.
Goll A; Glossmann H; Mannhold R
Naunyn Schmiedebergs Arch Pharmacol; 1986 Nov; 334(3):303-12. PubMed ID: 3027587
[TBL] [Abstract][Full Text] [Related]
39. Dihydropyridine [methyl-3H]PN 200-110 binding and myogenesis in intact muscle cells in vitro.
Navarro J
J Neurochem; 1986 Apr; 46(4):1166-9. PubMed ID: 3005507
[TBL] [Abstract][Full Text] [Related]
40. Binding of the dihydropyridine calcium channel blocker (+)-[3H] isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2, 6-dimethyl-3-pyridinecarboxylate (PN200-110) to RINm5F membranes and cells: characterization and functional significance.
Yaney GC; Stafford GA; Henstenberg JD; Sharp GW; Weiland GA
J Pharmacol Exp Ther; 1991 Aug; 258(2):652-62. PubMed ID: 1713965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
